MARKET

AUTL

AUTL

AUTOLUS THERAPEUTICS PLC
NASDAQ
1.940
+0.060
+3.19%
Opening 13:57 01/30 EST
OPEN
1.940
PREV CLOSE
1.880
HIGH
1.950
LOW
1.830
VOLUME
410.37K
TURNOVER
428.71K
52 WEEK HIGH
5.04
52 WEEK LOW
1.600
MARKET CAP
322.30M
P/E (TTM)
-1.0504
1D
5D
1M
3M
1Y
5Y
Mizuho picks its top stocks for 2023
Seeking Alpha · 3d ago
Mizuho Securities Remains a Buy on Autolus Therapeutics (AUTL)
TipRanks · 01/12 02:35
BRIEF-Autolus Therapeutics Collaborates With Cabaletta Bio For Autoimmune Disease Cell Therapies
Reuters · 01/09 13:43
Autolus Therapeutics Announces Collaboration With Cabaletta Bio For Use Of Autolus' Safety Switch System In Cell Therapies For Autoimmune Disease; Autolus To Receive Upfront Payment With Potential For Option Exercise Fees And Milestones
Benzinga · 01/09 12:05
FOCUS-Private equity acquires a taste for drug development
Reuters · 01/09 11:00
Autolus Announces Partial Exercise Of Underwriters' Option To Purchase 6.93M Additional ADSs At $2/ADS
Benzinga · 12/21/2022 21:03
BRIEF-Autolus Announces Partial Exercise Of Underwriters' Option To Purchase Additional Adss
Reuters · 12/21/2022 21:02
Dow Tumbles 100 Points; Silver Rises Over 2%
Benzinga · 12/09/2022 19:44
More
About AUTL
Autolus Therapeutics plc is a United Kingdom-based chimeric antigen receptor (CAR) T cell therapy company. The Company is developing programmed T cell therapies for the treatment of cancer. Using its suite of modular T cell programming technologies, the Company is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize cancer cells, break down their defense mechanisms and attack and kill these cells. Its clinical-stage pipeline comprises five programs developed in seven hematological and solid tumor indications. Its clinical-stage programs are Obe-cel (AUTO1), AUTO1/22, AUTO3, AUTO4, and AUTO6. AUTO1 is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. AUTO1/22 is a dual targeting CAR T cell-based therapy candidate based on obe-cel. AUTO3 is for the treatment of B-cell leukemias and lymphomas.

Webull offers kinds of Autolus Therapeutics PLC stock information, including NASDAQ:AUTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUTL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AUTL stock methods without spending real money on the virtual paper trading platform.